Shares in Acorda Therapeutics are sliding following the news that the company’s Parkinson’s drug has been linked to a potentially fatal side effect.
Fierce 15 winner Turnstone Biologics has poached Mike Burgess, MBChB, Ph.D., from Bristol-Myers Squibb to be its new head of R&D.
Using tech licensed from Yale University, Inozyme Pharma has emerged from stealth with $49 million and a mission.
The Parker Institute for Cancer Immunotherapy is sponsoring the trial, which will take place at the MD Anderson Cancer Center.
Flagship Pioneering has launched its latest biotech, Torque, as it hopes to power through using a new class of “deep-primed” immune cell therapies in cancer.
Heavily backed biotechs Denali Therapeutics and Odonate Therapeutics are looking to make hay while the sun shines by filing for two big IPOs.
Aquila BioMedical signed an extended contract with Macrophage Pharma to support its preclinical immuno-oncology programs.
Novartis has penned a new deal with Homology Medicines as it looks to boost its already impressive R&D work in cell and gene therapy.
Immuno-oncology startup Arcus Bioscience has got off another impressive round of funding, just over a year after emerging from stealth with $120 million.
Zymeworks must be spending a fortune on pens as it inks yet another deal, this time with Johnson & Johnson’s biotech unit.